Targeting key proximal drivers of type 2 inflammation in disease.
about
Developments in the field of allergy mechanisms in 2015 through the eyes of Clinical & Experimental Allergy.Snapshots of CD4+ T cell plasticity in the pathogenesis of allergic asthma.Post-transcriptional regulation of interleukin-10 in peripheral B cells of airway allergy patients.Suppression of colitis by adoptive transfer of helminth antigen-treated dendritic cells requires interleukin-4 receptor-α signalingIs a high-fiber diet able to influence ovalbumin-induced allergic airway inflammation in a mouse model?Personalized Medicine in Allergic Asthma: At the Crossroads of Allergen Immunotherapy and "Biologicals"Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months.Non-surgical management of chronic rhinosinusitis with nasal polyps based on clinical-cytological grading: a precision medicine-based approach.Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical TrialsHost regulation of liver fibroproliferative pathology during experimental schistosomiasis via interleukin-4 receptor alphaMicroRNA-98 interferes with thrombospondin 1 expression in peripheral B cells of patients with asthma.Epigenetics and allergy: from basic mechanisms to clinical applications.Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update.Chronic systemic inflammation originating from epithelial tissues.Dupilumab for the treatment of asthma.Targeted Therapy for Severe Asthma: Identifying the Right Patients.Commonality of the IL-4/IL-13 pathway in atopic diseases.Molecular aspects of allergens in atopic dermatitisThe mother-offspring dyad: microbial transmission, immune interactions and allergy development.IL-4 Haploinsufficiency Specifically Impairs IgE Responses against Allergens in Mice.Ribosomal protein S3 gene silencing protects against experimental allergic asthma.The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function.Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages.Microglia M2A Polarization as Potential Link between Food Allergy and Autism Spectrum Disorders.Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines.Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults.Dupilumab for the treatment of asthma.Drugmakers cling to dual IL-13/IL-4 blockbuster hopes.GATA-3-specific DNAzyme - A novel approach for stratified asthma therapy.Myosin light chains 9 and 12 are functional ligands for CD69 that regulate airway inflammation.Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.Cytokine Tuning of Intestinal Epithelial Function.
P2860
Q30275827-1551361C-E2A7-4A75-982C-42346C1CB404Q37329451-57CC2B1A-DABE-4E13-A9F4-2F9FB95EFD9CQ37553907-6BAF48CD-26A5-4FD2-840B-AB86604D1E93Q37589645-87568034-C9DE-4A33-AA98-D1DCF5B0B95BQ37593104-A2961161-0C14-415A-9352-099FA39F87DCQ37647767-DEC62482-85EB-4C3F-B7E1-37ADC243068FQ37692640-5C5B7761-A137-456C-8AB6-7D2206736D86Q37741477-42E0034D-D748-4BBB-8111-CB6A68969EDBQ38376812-8221D68C-06A7-4021-8BD5-70C58A32D32BQ38615196-A9746618-5A21-4A8E-990A-A16CC1D81F68Q38650873-FD7E4628-61C6-4564-81FD-33471E789BFCQ38742430-6C05E9C3-DA71-4E77-BF30-5882E259BE38Q38883893-BBE0C1B0-CE72-4A2A-A157-9D7F7B1AD758Q38960213-535FBB59-4377-4789-847A-E46AD250B57DQ39022174-A474FE2C-34C5-4CA5-838B-975159EC12F1Q39065311-6D8254A1-9B12-4AFC-9B63-D83D68B59803Q39170851-4461BB54-2564-4BDA-8C38-557716CCC7C4Q39378515-F327967D-4264-48E4-B8FC-B2D9AB57288AQ39447483-0C380F90-93FF-4D5A-91D5-5B8A0AE14C51Q40360998-6540AE93-8335-4E51-9F4C-2B876F42DB31Q40369676-09823DC4-1E48-46FC-B41A-089CB274AA18Q46320645-11113B50-4BF6-4869-9772-736459790AE2Q47101484-E1C0623C-7D59-4743-889E-7C89D7094DC4Q47168640-BE8D06DA-C4F9-4E1E-B1ED-5951D0AEA184Q47692692-164D2039-0C2D-4476-BADB-5B76B2A4C13FQ48158439-C1CCDAF1-A010-4175-9EA4-E904368C8BE1Q49184899-FC3E45FF-4C37-4BE2-8632-11011AD180E4Q49486790-9BCB6ADA-FB7D-4DE3-A879-EB0B05A27E09Q50105724-07456A09-5BA2-4927-9F6A-24B59B5B1C93Q51290628-23485392-1C3E-442B-9BAF-1ABF5D23A60FQ52836436-293E08F6-4EAE-4A5C-9722-F0D6FAF2D2F5Q54986959-AD37C351-01E0-41CF-B877-79100CEF7786Q55167657-2CCEEC64-B68A-4C58-B358-E7005D5E1E9C
P2860
Targeting key proximal drivers of type 2 inflammation in disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Targeting key proximal drivers of type 2 inflammation in disease.
@en
type
label
Targeting key proximal drivers of type 2 inflammation in disease.
@en
prefLabel
Targeting key proximal drivers of type 2 inflammation in disease.
@en
P2093
P2860
P356
P1476
Targeting key proximal drivers of type 2 inflammation in disease.
@en
P2093
Brandy L Bennett
George D Yancopoulos
Gianluca Pirozzi
Namita A Gandhi
Neil M H Graham
Neil Stahl
P2860
P2888
P356
10.1038/NRD4624
P577
2015-10-16T00:00:00Z
P5875
P6179
1006737496